A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca AB promotes employee well-being and patient education through social media; initiatives include AstraZeneca Holiday Camp and public health advisories on lupus and sun exposure
Published: July 26, 2024 by Industry Intelligence Inc.
AstraZeneca AB pushes healthcare innovation with lung cancer screening and STEM education; firm anticipates mid-teens revenue growth for 2024 due to global team's efforts
Published: July 25, 2024 by Industry Intelligence Inc.
FDA Advisory Committee reviewed AstraZeneca’s Imfinzi for resectable lung cancer; AEGEAN Phase III trial shows 32% risk reduction in recurrence, progression, or death vs. chemotherapy alone
Published: July 25, 2024 by AstraZeneca AB
AstraZeneca upgrades FY 2024 guidance for Total Revenue and Core EPS; aims for $80 billion in Total Revenue by 2030 with strong growth from approved medicines and late-stage pipeline
Published: July 25, 2024 by AstraZeneca AB
Patent Issued for Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors (USPTO 12024523)
Published: July 24, 2024 by Disease Prevention Daily

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count